MOMO'S BREAKOUT BOARD

[balamidas]

North Cell Pharmaceutical, Inc.&SSWC deal is close now with a seven figure payment for SSWC $$$

if we put events in a Chronological way

from june 21 PR :


http://finance.yahoo.com/news/SpeechSwitch-Inc-PINKSHEETS-iw-898046730.html?x=0&.v=1



In June 2009 the company obtained all rights to the GlynnTech, Inc. cancer drug delivery system, at cost. This includes one issued patent (US No. 7,637,889 B2), one pending application, three years of development work, a prototype, numerous CAD drawings of various embodiments, risk analysis and development pre-FDA filing history. Ken had three meetings with a major pharma company who expressed serious interest and has indicated that a contract will likely be offered for acquisition of the intellectual property after FDA filings have been made, but before FDA approval. If successful, a seven figure payment would be expected


and then come the the june 28 PR :

http://finance.yahoo.com/news/SpeechSwitch-Inc-USOTC-SSWC-iw-318914569.html?x=0&.v=1

"The third invention is a collaboration between Dr. Alain Martin and Ken Glynn, as co inventors, utilizing the same wound care technology, but including Dr. Martin's proprietary antioxidant, anti-inflammatory cell growth accelerants. Dr. Martin is the inventor of Neosporin and other successful products, and is currently the CEO of North Cell Pharmaceutical, Inc. SpeechSwitch and North Cell will be equal partners in this alliance."


and then come the 6 july PR :

http://finance.yahoo.com/news/SpeechSwitch-Inc-USOTC-SSWC-iw-3440709283.html?x=0&.v=1

Ken also announced that the first patent application on biodegradable bandages will be filed before July 12, 2010, that the second will be filed by July 30, 2010 and that the joint application with Dr. Alain Martin, (the inventor of Neosporin and other commercially successful products) will be filed shortly thereafter


and here come July 27 PR the confirmation of june 21 PR for the upcoming deal:

http://finance.yahoo.com/news/SpeechSwitch-Inc-USOTC-SSWC-iw-3506349087.html?x=0&.v=1

The second biodegradable disposable bandages patent application
will be filed August 1st as forecast, and the third application, with co-inventor Dr. Alain Martin (of Listerine and Neosporin fame) is in progress.


key words from june 21

"a contract will likely be offered for acquisition of the intellectual property after FDA filings have been made, but before FDA approval and a seven figure payment would be expected "

summary of events

FDA filings are almost DONE :)Deal is on the way for SSWC
with a seven figure payment $$$$$$


more about

Dr Alain Martin (the founder of Listerine and Neosporin) is the CEO of North Cell Pharmaceutical


http://www.northcellpharma.com/

http://www.northcellpharma.com/aboutus2.html

North Cell Pharmaceutical has developed a technology platform of patented ingredients (Skin Resuscitation Factor™ SRF™) that can down regulate inflammation (eliminate the destruction of nitric oxide to peroxynitrite), to enhance healing or to up regulate nitric oxide that can be used by the human body to kill bacterial, viral, and fungal infections and tumors. SRF™ can be used independently to create new products or can be added to existing products to enhance efficacy and to generate new product claims.

North Cell and GlaxoSmithKline Sign Agreement

North Cell Pharmaceutical, Inc. and GlaxoSmithKline Consumer Healthcare have entered into an Option and Development Agreement regarding North Cell’s Skin Resuscitation FactorTM (SRFTM ) technology for use in certain applications. The further details of the Agreement remain confidential.

SRFTM is a patent applied for technology that can be added to products in order to enhance product performance and the healing of any lesions or wounds associated with the underlying skin condition being treated.